Lewis Kelsey E, Lu Karen H, Klimczak Amber M, Mok Samuel C
Department of Obstetrics & Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2018 Feb 21;10(2):57. doi: 10.3390/cancers10020057.
Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman's management decisions.
目前，针对高危女性的卵巢癌筛查指南因不同组织而异。对于携带BRCA突变的患者，降低风险的手术仍然是确定性治疗的金标准，但研究进展为患者创造了更多短期选择以供考虑。由于治疗方案并不完美，女性在管理其BRCA突变状态时所涉及的决策可能会导致大量压力和担忧。本综述的目的是批判性地分析高危卵巢癌患者的筛查建议和替代方案，并评估这些差异和选择如何影响女性的管理决策。
